TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of Technologies Opens Business Opportunities Beyond CD19 CARTs
Albany, NY, August 18, 2016 --(PR.com)-- Market Research HUB has announced the addition of the "TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016" report to their huge collection of market research reports. The report “TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs” describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.
Browse Full Report with TOC - http://www.marketresearchhub.com/report/tcr-car-engineered-tcell-and-nk-cell-therapeutics-2016-convergence-of-technologies-opens-business-opportunities-beyond-cd19-carts-report.html
The report highlights and discusses
Company financing;
Business development & financing;
Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;
Engineered TCR T-cells, including TCR target discovery;
The current status of DLIs, CTLs and TILs;
Manufacturing of T-cells for adoptive cell therapy;
NK cells and CAR engineered NK cells;
International perspective on TCR & CAR T-cell and NK cell therapy; and
Key success factors & convergence of technologies.
The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017. Supported by Big Pharma money and billions of US$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.
However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles. Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.
Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.
Download sample pages: TCR & CAR Engineered T-Cells and NK-Cells 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
The analytical evaluation in this report is based on retrieval of information about and detailed description of the profiles of 67 companies and 67 cell therapy product candidates. Information was obtained from 193 scientific references (abstracts, full papers, reviews), press releases, financial information, annual reports, presentations and webcasts. All information sources are fully referenced, either as scientific references or by hyperlinks embedded on the source description for online access to the source.
Request for Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=784616
Who will benefit from this report?
Technology Officers
Corporate Development
Strategic Planning
Business Development & Licensing
Corporate Finance
Portfolio Management
Investors & Analysts
Clinical Development
Research & Development
About Market Research HUB
Market Research HUB (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : sales@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Browse Full Report with TOC - http://www.marketresearchhub.com/report/tcr-car-engineered-tcell-and-nk-cell-therapeutics-2016-convergence-of-technologies-opens-business-opportunities-beyond-cd19-carts-report.html
The report highlights and discusses
Company financing;
Business development & financing;
Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;
Engineered TCR T-cells, including TCR target discovery;
The current status of DLIs, CTLs and TILs;
Manufacturing of T-cells for adoptive cell therapy;
NK cells and CAR engineered NK cells;
International perspective on TCR & CAR T-cell and NK cell therapy; and
Key success factors & convergence of technologies.
The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017. Supported by Big Pharma money and billions of US$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.
However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles. Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.
Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.
Download sample pages: TCR & CAR Engineered T-Cells and NK-Cells 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
The analytical evaluation in this report is based on retrieval of information about and detailed description of the profiles of 67 companies and 67 cell therapy product candidates. Information was obtained from 193 scientific references (abstracts, full papers, reviews), press releases, financial information, annual reports, presentations and webcasts. All information sources are fully referenced, either as scientific references or by hyperlinks embedded on the source description for online access to the source.
Request for Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=784616
Who will benefit from this report?
Technology Officers
Corporate Development
Strategic Planning
Business Development & Licensing
Corporate Finance
Portfolio Management
Investors & Analysts
Clinical Development
Research & Development
About Market Research HUB
Market Research HUB (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : sales@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Contact
Market Research Hub
Sudip Saha
866-997-4948
www.marketresearchhub.com/
Sudip Saha
866-997-4948
www.marketresearchhub.com/
Contact
Categories